Chief Executive Officer
Dr. McCarthy joined CytomX in 2011 and has more than twenty years of experience in the biotechnology industry encompassing roles in R&D management, business development and financing. Following completion of his post-doctoral training at the DNAX Research Institute (now Merck Palo Alto) Dr. McCarthy held research leadership and program management roles at Millennium Pharmaceuticals where he managed therapeutic protein discovery programs. From Millennium he joined SGX Pharmaceuticals where he spearheaded a wide range of pharma partnerships as Vice President Business Development. He also served on the SGX management team that led a successful initial public offering in 2006 (SGXP; subsequently acquired by Lilly). Immediately prior to joining CytomX Dr. McCarthy was a transactional partner at Pappas Ventures responsible for investments in therapeutic, medical device and molecular diagnostic companies including LEAD Therapeutics (acquired by Biomarin), TyRx (acquired by Medtronic) and Lumena (acquired by Shire). Dr. McCarthy is an author on multiple peer-reviewed scientific publications, issued patents and filed patent applications. Dr. McCarthy received his B.Sc. in biochemistry and pharmacology at King's College, University of London; his M.B.A. from the Rady School of Management at UC San Diego; and a D. Phil. in cancer biology from St. John's College, University of Oxford.
Chief Scientific Officer and Head of Research and Early Development
Michael Kavanaugh joined CytomX as chief scientific officer and head of research and early development in January 2015. Prior to joining CytomX, Dr. Kavanaugh was senior vice president and chief scientific officer of Five Prime Therapeutics. Since joining the company in 2009, he held multiple positions in research and development and led the growth of the company’s therapeutic pipeline. Before Five Prime, Dr. Kavanaugh served as vice president of Novartis Vaccines & Diagnostics, Inc. and executive director of Oncology Biologics in the Novartis Institutes of Biomedical Research. He joined Novartis as part of the company’s acquisition of the Chiron Corporation in 2006, where he held positions as vice president and head of antibody and protein therapeutics research. Dr. Kavanaugh received his medical doctorate from Vanderbilt University and his bachelor’s degree in molecular biochemistry and biophysics from Yale University. He completed training in internal medicine, cardiovascular disease and molecular and cellular biology at the University of California, San Francisco and the Cardiovascular Research Institute. Dr. Kavanaugh also currently serves as an attending staff physician at the San Francisco Veterans Administration Medical Center and as an associate clinical professor of Medicine at the University of California, San Francisco.
Vice President, Process Sciences and Manufacturing Operations
Sridhar Viswanathan, Ph.D., joined CytomX in January 2015 as vice president of process sciences and manufacturing operations. Dr. Viswanathan joins CytomX from Perseid Therapeutics, a joint venture between Maxygen and Astellas that was subsequently acquired by Astellas, where he served as vice president of process development and manufacturing operations. In this capacity, he was responsible for all internal process development and external manufacturing operations at contract manufacturing organizations for advancing CTLA4-Ig Fc fusion products for autoimmune disease and organ transplant rejection. Before joining Perseid, Dr. Viswanathan spent several years at Maxygen directing process development and clinical manufacturing for next generation biologics programs, including PEGylated interferon alpha, PEG-G-CSF and FVIIa. Prior to this, he held positions at Coulter Pharmaceutical, Bayer Corporation, and Genentech. He received his doctorate in biochemistry from the University of Mississippi Medical Center and completed his postdoctoral training at Rockefeller University and Stanford University.
Vice President, Business Development and Alliance Management
Debanjan Ray has more than 10 years of experience in the biotechnology industry, including strategic consulting, venture capital and business development. Prior to joining CytomX in August of 2011, Mr. Ray was the vice president of business development at Itero Biopharmaceuticals, where he helped drive several collaborations including the company's partnership on its lead product with Watson Pharmaceuticals. Prior to Itero, Mr. Ray was an associate director of business development at Portola Pharmaceuticals. Previously, Mr. Ray was an associate in the life sciences venture practice at J.P. Morgan Partners and a business analyst in the healthcare practice at McKinsey & Company.
Mr. Ray holds a dual B.S. in chemical engineering and biology from the Massachusetts Institute of Technology and an M.B.A. from The Wharton School, University of Pennsylvania.
Vice President, Human Resources
Danielle Olander has 20 years of experience leading human resources management and operations, largely for life sciences companies. Before joining the CytomX team in August 2014, she served as the senior director of human resources management at Portola Pharmaceuticals, where she led all facets of human resources and developed effective strategies that enabled Portola to thrive through periods of change, as well as supported short and long-term business objectives. Prior to joining Portola, Ms. Olander served as senior human resources generalist for SuperGen (now Astex Pharmaceuticals), as well as held various human resources positions for companies such as SUGEN (acquired by Pfizer), and Kinetic Search, where she placed candidates for MedImmune, Amgen, Genentech and Abgenix.
Ms. Olander received her B.S. in human resource management from Colorado Technical University. She is chairperson of the Biotechnology HR Network (BHRN) and is an active member of the Society for Human Resources Management (SHRM) and World at Work (Total Rewards Association).
Consulting Chief Financial Officer
Sharon Tetlow joined CytomX in January 2015 as consulting chief financial officer. Ms. Tetlow has more than 25 years’ experience helping private and public biotech companies reach their financial and business objectives. She has raised hundreds of millions of dollars ranging from small to large private rounds to a very wide variety of public financings, has executed successful M&A transactions and helped steward resources to maximize outcomes. Building upon her start at Genentech in the eighties, she has served as CFO of a number of private and public companies including diaDexus, Cell Genesys, Pathwork, and Ocera. She earned her undergraduate degree at the University of Delaware, magna cum laude, and her MBA from Stanford University.